<DOC>
	<DOCNO>NCT01542242</DOCNO>
	<brief_summary>Liraglutide glucagon like peptide -1 ( GLP-1 ) agonist , approve use patient type 2 diabetes . Studies liraglutide show appetite suppressive effect associate weight loss patient type 2 diabetes . Liraglutide use treatment PWS limit one case report Cyganek et el ( See attach Citation ) . In case report , subject show improvement hemoglobin A1c body weight 14 week . The investigator plan examine use liraglutide single subject Prader Willi Syndrome type 2 diabetes one year . The investigator examine clinical parameter , clinical assessment hunger , biochemical marker diabetes lipid control .</brief_summary>
	<brief_title>Liraglutide Use Prader-Willi Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Prader Willi Syndrome , Diabetes Type 2 Previous family history Medullary Carcinoma Thyroid multiple endocrine neoplasia syndrome . Subjects acute chronic Pancreatitis</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Diabetes Mellitus Type 2</keyword>
	<keyword>Prader Willi Syndrome</keyword>
</DOC>